University of Saskatchewan's (USask) Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) team has seen promising results in their clinical trials for a COVID-19 vaccine.
Researchers say the study aims to assess how well people across a broad range of ages could be protected from Covid-19 with this new vaccine called ChAdOx1 nCoV-19.
After 28 days of being injected with the vaccine candidate, those in the trial had started to produce antibodies, and there was a response in T-cells, which protect the body from pathogens.
"Administering our vaccine in the first participants of this clinical trial is a significant achievement, bringing us one step closer toward addressing the fundamental need for a vaccine in the fight against the global COVID-19 pandemic", President and Chief Executive Officer of Novavax Stanley C. Erck said in a statement.
On April 17, the government launched a taskforce created to "rapidly develop a coronavirus vaccine", as well as scale up manufacturing so it can be quickly produced and delivered in mass quantities.
"Our study found that pre-existing Ad5 immunity could slow down the rapid immune responses to SARS-CoV-2 and also lower the peaking level of the responses".
"Everything is very accelerated, vaccines can take eight to 10 years to develop".
130 healthy people aged between 18 and 59 in Melbourne and Brisbane have volunteered to participate in the trial, which is being conducted by Australian firm Q-Pharm.
Dr Glenn said phase one results were expected by the end of July, and phase two by the end of the year.
Noting these limitations, the researchers said that further trials will be needed before the vaccine becomes available to all.
Mild adverse reactions included mild pain at the injection site in over half the vaccine recipients, fever in 46 per cent of the participants while 44 per cent complained of fatigue.
He said: "This new money will help mass-produce the Oxford vaccine so that if current trials are successful we have dosages to start vaccinating the United Kingdom population straight away".
"We said earlier in the year that there was an 80 percent chance of developing an effective vaccine by September", he told The Telegraph.
Discussions are also in progress with numerous governments around the world to increase access, and with the Serum Institute of India and other potential partners to increase production and distribution, AstraZeneca added.